Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Octreotide acetate
Indication
Acromegaly, Variceal haemorrhage in patients with cirrhosis, Prophylaxis of complications following pancreatic surgery, Secretory neoplasms, HIV-associated diarrhoea.
Instruction
Administer via Intramuscular/ Subcutaneous injection/ IV Infusion.
Drug interaction
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine. Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.
Malaysia
